Plain-English translation of NCT07032714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage research study testing whether — a new medication — works better when combined with (a treatment already approved for advanced multiple myeloma) and (a common steroid). The study will enroll about 25 patients with relapsed and refractory multiple myeloma — a type of blood cancer that has come back or stopped responding to previous treatments — to find the safest and most effective dose of this medication combination.
Multiple myeloma patients often run out of treatment options after trying several standard therapies. This medication addresses that gap by exploring whether adding to an existing approved treatment might help patients whose cancer has become resistant to other drugs.
You likely qualify if…
You likely don't qualify if…
You will receive injections of under the skin and take oral medications ( and ) on a schedule defined by the study, with treatment occurring in 28-day cycles. The first cycle involves more frequent doses to determine how well you tolerate the medication; subsequent cycles use a less frequent schedule. You will continue treatment as long as your cancer does not progress and you wish to remain in the study, with regular clinic visits to monitor your health and blood work.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States